Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) revealed on Monday that it has opened the first clinical site for its Phase I trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (R/R AML) in adults. Patient recruitment has now commenced.
The trial, designed as a dose-escalation study, aims to evaluate the safety profile of HG-CT-1 in R/R AML patients. Key secondary objectives include assessing the therapy's impact on efficacy, overall survival (OS), progression-free survival (PFS), and duration of response (DoR) in patients who achieve clinical responses.
AML is a particularly aggressive form of leukemia with poor survival rates, and existing treatments are limited. HG-CT-1 offers a promising alternative, harnessing CAR-T therapy to modify a patient's T-cells to target cancer cells.
The initiation of this trial marks a significant milestone for Hemogenyx Pharmaceuticals, advancing its lead asset into clinical testing at a renowned cancer research institution. The company is headquartered in London and has US operations in New York City, focusing on innovative treatments for blood and autoimmune diseases.
4basebio announces award of GMP certification for UK DNA manufacturing facility
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
Oncopeptides secures FDA approval to resume OPD5 clinical development
Spinogenix starts enrolment for SPG302 Phase 2 trial in schizophrenia
CRISM Therapeutics advances clinical trial for ChemoSeed
Eli Lilly reveals positive Phase two results for lepodisiran